Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 82.74

-1.3%

Dec 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2284)	2/25/2008 1:31:21 PM
From: Jibacoa	Read Replies (1) of 3722

CRME Has been up 35.96% & is still up 33.16% on volume of 1,867,244 which is ahead of its ADV & no recent news that I am aware. The stock is bouncing up from the $6 level. bigcharts.marketwatch.com On Dec 11 it announced that the Cardiovascular and Renal Drugs Advisory Committee of the FDA recommended the approval of its KYNAPID for rapid conversion of acute AF. The panel members voted 6 to 2 in favor of recommending to the FDA that KYNAPID be approved.(If approved, KYNAPID will be the first new drug therapy for the conversion of AF in 8 Yrs.) KYNAPID is the proposed brand name in for I.V. vernakalant HCl. The NDA was based on a 5 Yrs. clinical development & had been submitted in Dec 2006 & accepted for review in Feb 2007. The stock trades around 7.3xBV; the short ratio came down some, but still is around 5x the ADV. bigcharts.marketwatch.com It seems that selling the UXYOU option has little risk.g> Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next